Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $13.80 Consensus PT from Brokerages

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have been assigned a consensus rating of “Moderate Buy” from the five research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $13.80.

A number of research firms recently weighed in on AMRX. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday. Truist Financial set a $15.00 price target on shares of Amneal Pharmaceuticals in a report on Wednesday, January 7th. Barclays started coverage on Amneal Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $15.00 price objective for the company. Finally, Piper Sandler restated an “overweight” rating and set a $13.00 target price (up from $11.00) on shares of Amneal Pharmaceuticals in a research report on Friday, October 31st.

Insider Buying and Selling

In related news, EVP Nikita Shah sold 131,856 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total value of $1,571,723.52. Following the completion of the transaction, the executive vice president directly owned 146,403 shares in the company, valued at approximately $1,745,123.76. The trade was a 47.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ted C. Nark sold 50,000 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $11.72, for a total value of $586,000.00. Following the completion of the transaction, the director directly owned 291,029 shares in the company, valued at approximately $3,410,859.88. This represents a 14.66% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 231,856 shares of company stock valued at $2,743,724. Corporate insiders own 26.56% of the company’s stock.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of AMRX. Kendall Capital Management raised its holdings in shares of Amneal Pharmaceuticals by 33.5% during the 4th quarter. Kendall Capital Management now owns 34,265 shares of the company’s stock valued at $432,000 after buying an additional 8,595 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in Amneal Pharmaceuticals by 30.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,480,172 shares of the company’s stock valued at $18,739,000 after acquiring an additional 344,373 shares during the last quarter. Spire Wealth Management lifted its holdings in shares of Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after acquiring an additional 1,023 shares during the last quarter. Pallas Capital Advisors LLC bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter worth approximately $130,000. Finally, SG Americas Securities LLC boosted its stake in shares of Amneal Pharmaceuticals by 2,866.0% in the 4th quarter. SG Americas Securities LLC now owns 784,803 shares of the company’s stock valued at $9,889,000 after purchasing an additional 758,343 shares in the last quarter. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock opened at $13.39 on Monday. The firm has a market capitalization of $4.21 billion, a P/E ratio of 669.83 and a beta of 1.34. Amneal Pharmaceuticals has a one year low of $6.68 and a one year high of $13.75. The business has a fifty day moving average price of $12.60 and a 200-day moving average price of $10.64.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%.The business had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. Sell-side analysts expect that Amneal Pharmaceuticals will post 0.53 earnings per share for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.